Latest Period
n/a
Security Snapshot
Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (FBRX) Institutional Ownership
CUSIP: 34962G109
13F Institutional Holders and Ownership History from Q1 2019 to Q3 2024
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- FBRX on Nasdaq
- Shares outstanding
- 20,563,488
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- FBRX - Forte Biosciences, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 34962G109.
- Latest finished 13F holder period is not available.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 32 to 0 between Q2 2024 and Q3 2024.
- Reported value moved from $10,228,138 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Investment Quick Answers
What is CUSIP 34962G109?
CUSIP 34962G109 identifies FBRX - Forte Biosciences, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 34962G109:
Significant Owners of Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (FBRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 7.3% | 1,011,890 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||||
| MPM BioImpact LLC | 7.2% | 1,000,682 | MPM BioImpact LLC | 31 Mar 2026 | ||||
| Adage Capital Management, L.P. | 6.8% | 950,000 | Adage Capital Management, L.P. | 31 Mar 2026 | ||||
| ORBIMED ADVISORS LLC | 4.3% | 884,230 | ORBIMED ADVISORS LLC | 31 Mar 2026 | ||||
| Farallon Capital Partners, L.P. | 3.4% | $12,130 | 221,027 | Dapice Joshua J. | 31 Dec 2024 |
Institutional Holders of Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (FBRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2024 Q3 | 0 | $0 | -$10,134,239 | 0 | |
| 2024 Q2 | 19,046,477 | $10,228,138 | -$6,914 | $0.54 | 32 |
| 2024 Q1 | 19,048,634 | $13,285,300 | +$131,933 | $0.70 | 32 |
| 2023 Q4 | 18,862,822 | $15,499,549 | +$107,364 | $0.82 | 34 |
| 2023 Q3 | 16,699,691 | $11,053,360 | +$8,677,955 | $0.66 | 30 |
| 2023 Q2 | 3,463,993 | $3,601,147 | -$405,929 | $1.04 | 28 |
| 2023 Q1 | 3,865,337 | $3,904,404 | +$63,530 | $1.01 | 28 |
| 2022 Q4 | 3,801,902 | $3,800,654 | -$331,796 | $1.00 | 30 |
| 2022 Q3 | 2,668,691 | $2,852,110 | +$306,315 | $1.07 | 24 |
| 2022 Q2 | 2,308,331 | $3,001,130 | -$1,978,602 | $1.30 | 27 |
| 2022 Q1 | 3,886,365 | $5,675,151 | -$2,490,490 | $1.46 | 44 |
| 2021 Q4 | 5,360,245 | $11,473,214 | +$2,615,294 | $2.14 | 45 |
| 2021 Q3 | 3,861,588 | $11,432,424 | -$209,734,334 | $2.96 | 52 |
| 2021 Q2 | 8,609,574 | $289,376,415 | +$20,624,459 | $33.62 | 75 |
| 2021 Q1 | 7,968,324 | $273,111,000 | -$14,949,451 | $34.27 | 62 |
| 2020 Q4 | 8,392,546 | $305,570,000 | +$56,276,590 | $36.41 | 49 |
| 2020 Q3 | 6,803,921 | $330,057,000 | +$190,204,632 | $48.51 | 45 |
| 2020 Q2 | 2,883,976 | $42,049,000 | +$42,049,000 | $14.58 | 22 |
| 2020 Q1 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q4 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q3 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q2 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q1 | 66 | $2,000 | $30.30 | 1 |